Windlas Biotech Ltd (WINDLAS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Windlas Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Cyber Security Incident
Others (Uncategorized) · 31 Oct 2026, 12:33 am
Windlas Biotech Reports Cyber Security Incident With No Material Operational Impact Windlas Biotech experienced a cyber security incident on 30th Oct'26. The company confirmed that the incident has caused no material impact on its core business operations, financial performance, or business continuity. A detailed technical assessment is currently underway, and appropriate remedial and preventive measures are being implemented to secure systems.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 05 Nov 2026, 5:30 am
Schedule of Conference Call to discuss financial performance for quarter and half year ended September 30, 2026
Intimation · 06 Nov 2026, 11:30 am
Windlas Biotech Schedules Q2 & H1FY27 Earnings Conference Call Windlas Biotech Limited will host an earnings conference call on 6th Nov'26 at 11:30 AM IST to discuss its financial performance for the quarter and half-year ended 30th Sep'26 (Q2 & H1FY27). The call will feature key management representatives, including Managing Director Hitesh Windlass and CEO & CFO Komal Gupta. Primary domestic dial-in numbers include +91 22 6280 1256 and +91 22 7115 8157, alongside international toll-free options for key global regions.
WINDLAS BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 05 Nov 2026, 5:30 am
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the un-audited standalone ....
Intimation · 05 Nov 2026, 5:30 am
Windlas Biotech Board Meeting Scheduled for 5th Nov'26 to Consider Q2 Results Windlas Biotech Limited's Board of Directors is scheduled to meet on 5th Nov'26 to consider and approve the un-audited standalone financial results for the quarter and half year ended 30th Sep'26. In compliance with SEBI insider trading regulations, the trading window for designated persons, closed since 1st Oct'26, will reopen 48 hours after the declaration of the financial results.
Resignation of Mr. Vivek Dhariwal (DIN: 02826679), Independent Director of the Company, with effect from close of business hours on October 12, 2026
Change in Management · 13 Oct 2026, 9:47 pm
Windlas Biotech Board Chairman Vivek Dhariwal Resigns as Independent Director Windlas Biotech Limited announced the resignation of Independent Director Mr. Vivek Dhariwal, effective close of business hours on 12th Oct'26, citing personal reasons and prior commitments. Consequently, Dhariwal also ceased to serve as Chairman of the Board and member of both the Nomination and Remuneration Committee and the Corporate Social Responsibility Committee. The company confirmed there were no other material reasons behind his resignation, and he holds no other directorships or committee positions in listed entities.
Intimation of change in the composition of the Board in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Change in Management · 12 Oct 2026, 11:51 pm
Windlas Biotech Announces Board Restructuring and Independent Director Changes Windlas Biotech approved key board changes effective 12th Oct'26. Board Chairman and Independent Director Vivek Dhariwal resigned due to personal reasons and prior commitments, stepping down from the Nomination & Remuneration Committee and CSR Committee. Concurrently, the board appointed Aashish Mehra and Soni Saran Singh as Additional Independent Directors for five consecutive years, subject to shareholder approval. Mehra brings over two decades of strategy and pharma industry experience, while Singh brings over three decades of leadership across electronics manufacturing and technology sectors.
Appointment and Resignation of Directors
Others (Uncategorized) · 12 Oct 2026, 11:48 pm
Windlas Biotech Announces Board Restructuring With New Independent Director Appointments Windlas Biotech Limited approved key board changes effective 12th Oct'26. Mr. Vivek Dhariwal resigned as Independent Director and Board Chairman, citing personal reasons. Concurrently, the Board approved the appointments of Mr. Aashish Mehra, possessing over two decades of pharma consulting experience, and Mr. Soni Saran Singh, Founder & MD of NMTronics India, as Additional Independent Directors for five-year terms, subject to shareholder approval.
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Intimation · 01 Sept 2026, 11:11 pm
Windlas Biotech Schedules Virtual Investor and Analyst Meetings for Sep 7, 2026 Windlas Biotech will hold virtual investor and analyst meetings on Mon, 7th Sep'26. Management will meet with ICICI Direct (2:00 PM), Bajaj Broking (3:00 PM), a group of investors (4:00 PM), and Haitong Securities (5:00 PM). The discussions will be based on publicly available information, with no unpublished price sensitive information (UPSI) to be shared. The company noted that meeting schedules are subject to change.
Q1 FY27 Earnings Conference Call Transcript enclosed.
Transcript · 14 Aug 2026, 8:29 pm
Audio Recording Q1 conference call
Audio / Video · 11 Aug 2026, 7:34 pm
Windlas Biotech Publishes Audio Recording of Q1 FY27 Earnings Call Windlas Biotech (NSE: WINDLAS) has uploaded the audio recording of its investor/analyst conference call held on 11 Aug'26. The call discussed the unaudited standalone financial results for the quarter ended 30 Jun'26. A full transcript of the call will be shared with stock exchanges and uploaded to the company's website in due course. The recording is currently available on the company's website.
Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'
Press Release · 10 Aug 2026, 9:45 pm
Windlas Biotech Q1FY27: Strong CDMO Growth Drives Record Revenue and Profit Windlas Biotech reported a strong Q1FY27, posting its 14th consecutive quarter of record revenue at ₹248 crores, up 18% YoY. Growth was driven by the Generic Formulations CDMO segment, which grew 29% YoY to ₹207 crores. Adjusted PAT rose 37% YoY to ₹25 crores with a margin of 10%, while adjusted EBITDA grew 26% to ₹34 crores. The Trade Generics segment declined 32% YoY to ₹30 crores. The company also completed a ₹47 crore share buyback and declared a ₹13 crore dividend for FY26.
Investor Presentation - Q1 FY27 enclosed
Investor Presentation · 10 Aug 2026, 9:42 pm
Windlas Biotech Posts Strong Q1 FY27 Revenue and Profit Growth Windlas Biotech reported its highest-ever quarterly revenue of ₹248 Cr in Q1 FY27, an 18% YoY increase. Adjusted PAT grew 37% YoY to ₹25 Cr with margins expanding to 10.0%. The strong performance was driven by the Generic Formulations CDMO segment, which grew 29% YoY to ₹207 Cr. Exports also surged 79% YoY to ₹11 Cr. The Trade Generics & Institutional vertical declined 32% YoY to ₹30 Cr. EPS improved to ₹8.46. The company completed a ₹47 Cr share buyback without promoter participation.
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Financial Result · 10 Aug 2026, 8:59 pm
Windlas Biotech Q1 FY27 Revenue Grows 18% YoY; Profit Remains Flat Windlas Biotech reported Q1 FY27 standalone revenue from operations at ₹2,481.0M, an 18.1% YoY and 4.0% QoQ increase. Profit After Tax (PAT) for the quarter ending 30 Jun'26 was ₹176.5M, nearly flat compared to ₹176.7M YoY, but up 10.2% QoQ. Total expenses grew 19.9% YoY to ₹2,302.8M, driven by a 34.5% YoY rise in material costs. Basic EPS stood at ₹8.46 vs. ₹8.43 in the prior year's quarter. The company noted the dissolution of its US subsidiary effective 31 Mar'26.
approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2026.
Outcome · 10 Aug 2026, 8:53 pm
Windlas Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Million) ■ Revenue: 2,481 (+18.1% YoY | +4.0% QoQ) ■ EBITDA: 267 (+0.6% YoY | +5.7% QoQ) ■ EBITDA Margin (%): 10.8 (-187 bps YoY | +17 bps QoQ) ■ PAT: 177 (-0.1% YoY | +10.2% QoQ) ■ EPS (INR): 8.32 (-0.2% YoY | +10.9% QoQ)
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
Intimation · 05 Aug 2026, 8:32 pm
Windlas Biotech Schedules Q1FY27 Earnings Conference Call for August 11, 2026 Windlas Biotech has scheduled a conference call to discuss its financial performance for the quarter ended Jun 30, 2026. The call will take place on Tue, Aug 11, '26, at 11:30 AM IST. Management representatives include Mr. Hitesh Windlass (Managing Director) and Ms. Komal Gupta (CEO and CFO), who will address investors and analysts. The company has provided dial-in numbers for domestic and international participants to join the event. Further details are available on the company website.
Schedule of Conference Call to discuss financial performance for quarter ended June 30, 2026
Intimation · 11 Aug 2026, 11:30 pm
Windlas Biotech Schedules Q1FY27 Earnings Call for Aug 11 Windlas Biotech (NSE: WINDLAS) has scheduled an earnings conference call to discuss its Q1FY27 financial performance for the quarter ended Jun 30, 2026. The call will take place on Tue, Aug 11, 2026, at 11:30 AM IST. Key management, including Managing Director Mr. Hitesh Windlass and CEO/CFO Ms. Komal Gupta, will be present to discuss the results and outlook. This event provides an opportunity for investors and analysts to gain insights into the company's recent performance and future strategy.
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....
Intimation · 10 Aug 2026, 5:30 am
Windlas Biotech Board Meeting Set for Aug 10 to Approve Q1FY27 Results Windlas Biotech (NSE: WINDLAS) will hold a Board of Directors meeting on 10 Aug'26 to consider and approve the un-audited standalone financial results for the quarter ended 30 Jun'26. In compliance with insider trading regulations, the trading window for designated persons has been closed since 01 Jul'26 and will re-open 48 hours after the financial results are declared.
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
Annual General Meeting · 24 Jul 2026, 10:58 pm
Submission of Combined Voting Results and Scrutinizer's Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') ....
Annual General Meeting · 24 Jul 2026, 10:09 pm
Proceedings of 25th Annual General Meeting of the Company held on July 23, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Annual General Meeting · 23 Jul 2026, 8:29 pm
Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015
Intimation · 10 Jul 2026, 12:57 am
Windlas Biotech Schedules Virtual Investor Group Meeting Windlas Biotech (NSE: WINDLAS) has scheduled a virtual group meeting with investors and analysts for 14th Jul'26, starting at 3:00 PM onwards. The company confirmed that discussions will be limited to publicly available information, and no unpublished price-sensitive information (UPSI) will be disclosed. The schedule is subject to potential changes based on exigencies from any of the involved parties. This intimation was filed with the exchanges on 9th Jul'26 as per SEBI disclosure requirements.
Intimation of record date/ cut-off date for the 25th AGM and evoting
Annual General Meeting · 02 Jul 2026, 1:10 am
Annual Report for FY26
Others (Uncategorized) · 02 Jul 2026, 12:53 am
Notice of 25th AGM to be held on July 23, 2026
Annual General Meeting · 01 Jul 2026, 7:42 pm